Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine
Michael E. Thase(Veterans Health Administration), Michael J. Detke(Eli Lilly (United States)), Beth A. Pangallo(Eli Lilly (United States)), Craig Mallinckrodt(Biogen (United States)), Curtis G. Wiltse(Eli Lilly (United States)), Pierre V. Trân(Eli Lilly (United States))
Cited by 119
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
|Controlled Clinical Trials|2004|1.1k
Frontiers of cognitive therapy
|General Hospital Psychiatry|1997|1.1k